Friday, 19 Jul 2019

You are here

Breast Implant Study: More Worries or Not?

The Annals of Surgery reports on an anlaysis of FDA-mandated postmarket studies, including nearly 100,000 breast implant pprocedures, that showed silicone implants to be associated with higher rates of  Sjögren's syndrome, scleroderma, rheumatoid arthritis, stillbirth, and melanoma. (Citation source: http://bit.ly/2xu76Ua)

Among 99,993 patients they found that 56% of the implants were silicone for primary augmentation. In the short term, rupture rate is higher for saline-filled implants compared to silicone gel-filled implants (2.5% vs. 0.5%), but capsular contracture was higher for silicone (5.0% vs. 2.8%).

Compared with normative population data, silicone implants are associated with higher rates of Sjögren's syndrome (Standardized incidence ratio [SIR] = 8.14), scleroderma (SIR 7.00), rheumatoid arthritis (SIR 5.96), stillbirth (SIR 4.50), and melanoma (SIR 3.71). 

While this is the largest study of breast implant outcomes, the risk of certain autoimmune (unsubstantiated) diagnoses were rare. 

The FDA provided an editorial response noting to "significant shortcomings" with the study's methodology, inconsistencies in the data and potential sources of bias.

The issue of autoimmune consequences to augmentation mammoplasty dates back to controversies seen in the U.S. market in 1992, leading to a moratorium on silicone implants. 

In 2006, the FDA lifted the 14-year moratorium but required each manufacturer (J&J's Mentor, and Allergan) to invest in large post-approval studies to further characterize the safety and outcomes of their breast implants. 

The authors call for more data and better methodologies to study this issue.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Cardiovascular Disease Increased in Hospitalized Lupus Patients

Systemic lupus erythematosus (SLE) patients who are hospitalized have an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) and its individual phenotypes of coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease. 

Pregnancy Outcomes Improve in Lupus

Pregnancy for patients with lupus has long been considered high risk and associated with both medical and obstetric complications, but outcomes have improved over the last 2 decades and continue to improve. The large decline in in-hospital maternal mortality was greater for lupus pregnancies than for non-lupus pregnancies. Findings from a retrospective cohort study are published in Annals of Internal Medicine.

Blinded by the Use of Antimalarials in Lupus?

Editor's note: July 1 - 5, RheumNow is running the best of EULAR 2019 meeting. Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD. But, if you prescribe them long term, will your patients go blind?

Disparities in Lupus Survival

MMWR has published the outcomes from the Georgia Lupus Registry between 2002 and 2016, finding that black women were not only more likely to die from lupus than white lupus patients; but they died on average 13 years earlier (mean age 51.8 and 52.3 years, respectively) than whites (mean age 64.4 and 65.0 years, respectively). Black women with lupus were 3.34 times more likely to die than black women in the general population, while white women with lupus were 2.43 times more likely to die than white women in the general population. None of the white women with lupus died within 5 years of diagnosis, while mortality was elevated for black women from the date of diagnosis on.

DMARD Success in Myositis-Related Interstitial Lung Disease

It is estimated that up to 50% of patients with idiopathic inflammatory myopathy will be complicated by interstitial lung disease, and having ILD may impart a poor prognosis. A recent review of the Johns Hopkins myositis-related ILD cohort has shown that azathioprine and mycophenolate mofetil use is associated improved lung function and less prednisone use.